Successful Treatment of Nonbacterial Thrombotic Endocarditis and Disseminated Intravascular Coagulation in a Patient With Advanced Lung Adenocarcinoma Using Osimertinib [0.03%]
奥希替尼成功治疗晚期肺腺癌患者的非细菌性赘生物心内膜炎和弥漫性血管内凝血
Hsiao-Chin Shen,Yen-Fu Hsu,Chi-Lu Chiang
Hsiao-Chin Shen
Rapid Onset of Takotsubo Cardiomyopathy Induced by an Infusion Reaction to Pembrolizumab in a Patient with NSCLC [0.03%]
NSCLC患者在使用Pembrolizumab过程中出现输液反应，迅速引发心尖球囊综合症
Yuki Okamatsu,Kazuya Tsubouchi,Ritsu Ibusuki et al.
Yuki Okamatsu et al.
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes [0.03%]
来自法国胸科肿瘤学研究联合会生物标志物法国研究的KRAS突变亚型晚期NSCLC患者的预后结果
Anne-Marie Ruppert,Michèle Beau-Faller,Didier Debieuvre et al.
Anne-Marie Ruppert et al.
Introduction: KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. ...
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC [0.03%]
RET融合：成为NSCLC可靶向的分子驱动因素之一
Badi El Osta,Suresh S Ramalingam
Badi El Osta
The era of precision medicine has resulted in the identification of a number of genomic alterations that can be targeted with novel therapies. In lung adenocarcinomas, a histology structure that accounts for nearly 50% of all cases of lung ...
Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation [0.03%]
免疫检查点抑制剂所致的获得性凝血障碍：炎症和凝血之间的一种被忽视的关系
Jacinth J Joseph,Arun Rajan,James L Gulley et al.
Jacinth J Joseph et al.
Introduction: Immune-related adverse events affecting virtually every organ system have been described in individuals receiving immune checkpoint inhibitors. The spectrum of hematologic adverse effects is diverse and incl...
A Catalog of 5' Fusion Partners in ROS1-Positive NSCLC Circa 2020 [0.03%]
ROS1阳性NSCLC circa 2020的5'融合伴侣的目录
Sai-Hong Ignatius Ou,Misako Nagasaka
Sai-Hong Ignatius Ou
ROS1 fusion-positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which d...
Olfa Trabelsi-Grati,Elsy El-Alam,Samia Melaabi et al.
Olfa Trabelsi-Grati et al.
Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin [0.03%]
用环孢霉素成功治疗的durvalumab引起的继发性纯红细胞再生障碍
Kageaki Watanabe,Rui Kitadai,Shingo Kitagawa et al.
Kageaki Watanabe et al.
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC [0.03%]
多激酶抑制剂Ponatinib治疗晚期RET基因重排的非小细胞肺癌二期研究
Justin F Gainor,Shirish Gadgeel,Sai-Hong I Ou et al.
Justin F Gainor et al.
Introduction: RET rearrangements define a distinct molecular subset of NSCLC. The multikinase inhibitor ponatinib reveals potent activity in preclinical models of RET-rearranged NSCLC. ...
Satoshi Ikeda,Hiromasa Arai,Akimasa Sekine et al.
Satoshi Ikeda et al.